The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has been Upgraded to Overweight from Sector Weight by KeyBanc Capital Markets in its latest research note that was published on April 01. Raymond James analysts bumped their recommendation on ANGO stock from Mkt Perform to Outperform in a separate flash note to investors on April 03. Analysts at Craig Hallum downgraded the stock to a Hold call from its previous Buy stance, in a research note that dated back to January 05.
AngioDynamics,’s stock is covered by 4 analysts, with none of them rating the stock as Buy. It has been deemed to have strong buy by 1 of the analysts, 3 of them have rated it as a Hold while none of them rated it as sell. The situation was different a month ago when the stock was rated as a Buy by only none analysts. 1 of them rated it as strong buy with 3 of them recommended investors to Hold on to the stock. Meanwhile, none analyst(s) rated it as a sell. The above data shows that ANGO has an average analyst rating of 2.75.
AngioDynamics, Inc., which has current market capitalization of above $728 Million, published its last quarter earnings on May 31, 2019. The company was able to amass $96.3 million in revenue. This figure is $3.97 million more than what analysts had expected which was $92.33 million. During the first quarter of the year, AngioDynamics, also recorded $0.25 earnings per share (EPS) which is $0 above the $0.25 estimated by Thomson Reuter’s analyst, leading to a surprise factor of 1.96%.
ANGO surged by $0.07 during the normal trading session on Tuesday and reaching a high of $19.74 during the day while it closed the day at $19.11. The AngioDynamics, stock had a low trading volume of 0.20 million shares on that day, which is low compared to the average daily volume of 204.04M shares. ANGO has also lost 3.63% of its value over the past 7 days. However, the stock has declined by 2.10% in the 3 months of the year. Over the past six months meanwhile, it has lost 16.55% while it has lost 5.07% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -13.49% from its 3 months high price. However, taking another look at ANGO will indicate that it is trading +3.52% away from its 90-day low. Looking at the bigger picture, the AngioDynamics, Inc. stock has dropped by -25% from its 52-week high while it has surged by +5.52% from its 52-week low price.
On July 16, 2019 Gould Kevin J, Director sold 13650 shares of the company. The average price for that transaction was $21.45 per share, which meant that Gould Kevin J earned $292792.5 selling the stocks. The sale was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with EVP and CFO, Greiner Michael selling 1939 shares of this stock on November 07, 2018. The average selling price for the stock was $21.53 per share, with the sold stock accruing $41746.67. Following this transaction, the EVP and CFO Greiner Michael now holds 55124 shares of the company, which is worth around $1084289.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 8.31%. This figure is better than the company’s 20-day Raw Stochastic average which currently stands at 3.79%. Over the past 20 days, AngioDynamics,’s Stochastic %K stood at 10.89% while its Stochastic %D was revealed to be 16.44%.